Comparison on the prevention of household influenza infection between baloxavir marboxil and neuraminidase inhibitors using health insurance claims database -2018/2019 influenza season-

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 08 Feb 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Baloxavir-marboxil (Primary) ; Laninamivir; Oseltamivir; Peramivir; Zanamivir
Indications Influenza virus infections
Focus Therapeutic Use
Sponsors Shionogi

01 Feb 2022 Results Comparing of intra-familial transmission of influenza virus from index patients treated with baloxavir marboxil or oseltamivir using an influenza transmission model and a health insurance claims database, published in the Clinical Infectious Diseases
20 Jan 2021 Status changed from active, no longer recruiting to completed.
26 Oct 2020 Results comparing the incidence of household transmission in the 2018-2019 influenza season when index patients were treated with either BXM or a NAI published in the Clinical Infectious Diseases

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com